BULLFROG AI HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Basic
BULLFROG AI HOLDINGS, INC. (BFRG) reported Net Income (Loss) Available to Common Stockholders, Basic of -$6.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-19
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$1.48M.
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$1.55M.
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$1.45M.
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$2.02M.
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$6.50M.
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$7.04M.
- BULLFROG AI HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$5.36M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$3.03M derived: sum of 2 quarters · filed 2026-03-19 | -$4.48M derived: sum of 3 quarters · filed 2026-03-19 | -$6.50M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$1.55M 10-Q · filed 2025-11-14 | -$3.00M derived: sum of 2 quarters · filed 2025-11-14 | -$5.02M 10-Q · filed 2025-11-14 | -$6.76M derived: sum of 4 quarters · filed 2026-03-19 |
| 2025-06-30 | -$1.45M 10-Q · filed 2025-08-13 | -$3.47M 10-Q · filed 2025-08-13 | -$5.21M derived: sum of 3 quarters · filed 2026-03-19 | -$6.97M derived: sum of 4 quarters · filed 2026-03-19 |
| 2025-03-31 | -$2.02M 10-Q · filed 2025-05-13 | -$3.76M derived: sum of 2 quarters · filed 2026-03-19 | -$5.52M derived: sum of 3 quarters · filed 2026-03-19 | -$7.14M derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$3.51M derived: sum of 2 quarters · filed 2026-03-19 | -$5.12M derived: sum of 3 quarters · filed 2026-03-19 | -$7.04M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$1.76M 10-Q · filed 2025-11-14 | -$3.38M derived: sum of 2 quarters · filed 2025-11-14 | -$5.30M 10-Q · filed 2025-11-14 | -$6.59M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$1.61M 10-Q · filed 2025-08-13 | -$3.53M 10-Q · filed 2025-08-13 | -$4.83M derived: sum of 3 quarters · filed 2025-08-13 | -$6.08M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$1.92M 10-Q · filed 2025-05-13 | -$3.22M derived: sum of 2 quarters · filed 2025-05-13 | -$4.47M derived: sum of 3 quarters · filed 2025-05-13 | -$5.95M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$2.55M derived: sum of 2 quarters · filed 2025-03-14 | -$4.03M derived: sum of 3 quarters · filed 2025-03-14 | -$5.36M 10-K · filed 2025-03-14 |
| 2023-09-30 | -$1.25M 10-Q · filed 2024-11-08 | -$2.73M derived: sum of 2 quarters · filed 2024-11-08 | -$4.06M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | -$1.48M 10-Q · filed 2024-08-07 | -$2.81M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$1.33M 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |